ただし、追加料金で日本語のレポートが入手できる場合もある。
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
4.2.1 Regulatory Landscape
4.2.1.1 United States
4.2.1.2 Canada
4.2.1.3 European Union
4.2.1.4 China
4.2.1.5 India
4.2.1.6 Japan
4.2.1.7 South Korea
4.2.1.8 Australia
4.2.1.9 Russia
4.2.1.10 Brazil
4.2.1.11 Mexico
4.2.1.12 Turkey
4.2.1.13 GCC Countries
4.2.1.14 Israel
4.2.2 Product Pipeline for New Vaccines
4.2.2.1 Product Pipeline for HIV
4.2.2.2 Product Pipeline for Zika Virus
4.2.2.3 Product Pipeline for Ebola Virus
4.2.2.4 Product Pipeline for COVID-19
5 Global Vaccine Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Technology
6.1 Conjugate Vaccines
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Inactivated and Subunit Vaccines
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Live Attenuated Vaccines
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Recombinant Vaccines
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Toxoid Vaccines
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Patient Type
7.1 Paediatric
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Adult
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Indication
8.1 Bacterial Diseases
8.1.1 Market Trends
8.1.2 Major Types
8.1.2.1 Meningococcal Disease
8.1.2.1.1 Market Trends
8.1.2.1.2 Market Forecast
8.1.2.2 Pneumococcal Disease
8.1.2.2.1 Market Trends
8.1.2.2.2 Market Forecast
8.1.2.3 Diphtheria/Tetanus/Pertussis (DPT)
8.1.2.3.1 Market Trends
8.1.2.3.2 Market Forecast
8.1.2.4 Tuberculosis
8.1.2.4.1 Market Trends
8.1.2.4.2 Market Forecast
8.1.2.5 Haemophilus Influenzae (Hib)
8.1.2.5.1 Market Trends
8.1.2.5.2 Market Forecast
8.1.2.6 Typhoid
8.1.2.6.1 Market Trends
8.1.2.6.2 Market Forecast
8.1.2.7 Others
8.1.2.7.1 Market Trends
8.1.2.7.2 Market Forecast
8.1.3 Market Forecast
8.2 Viral Diseases
8.2.1 Market Trends
8.2.2 Major Types
8.2.2.1 Hepatitis
8.2.2.1.1 Market Trends
8.2.2.1.2 Market Forecast
8.2.2.2 Influenza
8.2.2.2.1 Market Trends
8.2.2.2.2 Market Forecast
8.2.2.3 Human Papillomavirus (HPV)
8.2.2.3.1 Market Trends
8.2.2.3.2 Market Forecast
8.2.2.4 Measles/Mumps/Rubella (MMR)
8.2.2.4.1 Market Trends
8.2.2.4.2 Market Forecast
8.2.2.5 Rotavirus
8.2.2.5.1 Market Trends
8.2.2.5.2 Market Forecast
8.2.2.6 Herpes Zoster
8.2.2.6.1 Market Trends
8.2.2.6.2 Market Forecast
8.2.2.7 Varicella
8.2.2.7.1 Market Trends
8.2.2.7.2 Market Forecast
8.2.2.8 Japanese Encephalitis
8.2.2.8.1 Market Trends
8.2.2.8.2 Market Forecast
8.2.2.9 Rubella
8.2.2.9.1 Market Trends
8.2.2.9.2 Market Forecast
8.2.2.10 Polio
8.2.2.10.1 Market Trends
8.2.2.10.2 Market Forecast
8.2.2.11 Rabies
8.2.2.11.1 Market Trends
8.2.2.11.2 Market Forecast
8.2.2.12 Dengue
8.2.2.12.1 Market Trends
8.2.2.12.2 Market Forecast
8.2.2.13 Others
8.2.2.13.1 Market Trends
8.2.2.13.2 Market Forecast
8.2.3 Market Forecast
9 Market Breakup by Route of Administration
9.1 Intramuscular and Subcutaneous Administration
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Oral Administration
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Product Type
10.1 Multivalent Vaccine
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Monovalent Vaccine
10.2.1 Market Trends
10.2.2 Market Forecast
11 Market Breakup by Treatment Type
11.1 Preventive Vaccine
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Therapeutic Vaccine
11.2.1 Market Trends
11.2.2 Market Forecast
12 Market Breakup by End User
12.1 Hospitals
12.1.1 Market Trends
12.1.2 Market Forecast
12.2 Clinics
12.2.1 Market Trends
12.2.2 Market Forecast
12.3 Vaccination Centres
12.3.1 Market Trends
12.3.2 Market Forecast
12.4 Academic and Research Institutes
12.4.1 Market Trends
12.4.2 Market Forecast
12.5 Others
12.5.1 Market Trends
12.5.2 Market Forecast
13 Market Breakup by Distribution Channel
13.1 Hospital Pharmacies
13.1.1 Market Trends
13.1.2 Market Forecast
13.2 Retail Pharmacies
13.2.1 Market Trends
13.2.2 Market Forecast
13.3 Institutional Sales
13.3.1 Market Trends
13.3.2 Market Forecast
13.4 Others
13.4.1 Market Trends
13.4.2 Market Forecast
14 Market Breakup by Region
14.1 North America
14.1.1 United States
14.1.1.1 Market Trends
14.1.1.2 Market Forecast
14.1.2 Canada
14.1.2.1 Market Trends
14.1.2.2 Market Forecast
14.2 Asia Pacific
14.2.1 China
14.2.1.1 Market Trends
14.2.1.2 Market Forecast
14.2.2 Japan
14.2.2.1 Market Trends
14.2.2.2 Market Forecast
14.2.3 India
14.2.3.1 Market Trends
14.2.3.2 Market Forecast
14.2.4 South Korea
14.2.4.1 Market Trends
14.2.4.2 Market Forecast
14.2.5 Australia
14.2.5.1 Market Trends
14.2.5.2 Market Forecast
14.2.6 Others
14.2.6.1 Market Trends
14.2.6.2 Market Forecast
14.3 Europe
14.3.1 Germany
14.3.1.1 Market Trends
14.3.1.2 Market Forecast
14.3.2 France
14.3.2.1 Market Trends
14.3.2.2 Market Forecast
14.3.3 United Kingdom
14.3.3.1 Market Trends
14.3.3.2 Market Forecast
14.3.4 Italy
14.3.4.1 Market Trends
14.3.4.2 Market Forecast
14.3.5 Spain
14.3.5.1 Market Trends
14.3.5.2 Market Forecast
14.3.6 Russia
14.3.6.1 Market Trends
14.3.6.2 Market Forecast
14.3.7 Others
14.3.7.1 Market Trends
14.3.7.2 Market Forecast
14.4 Latin America
14.4.1 Brazil
14.4.1.1 Market Trends
14.4.1.2 Market Forecast
14.4.2 Mexico
14.4.2.1 Market Trends
14.4.2.2 Market Forecast
14.4.3 Others
14.4.3.1 Market Trends
14.4.3.2 Market Forecast
14.5 Middle East and Africa
14.5.1 Turkey
14.5.1.1 Market Trends
14.5.1.2 Market Forecast
14.5.2 GCC Countries
14.5.2.1 Market Trends
14.5.2.2 Market Forecast
14.5.3 Israel
14.5.3.1 Market Trends
14.5.3.2 Market Forecast
14.5.4 Others
14.5.4.1 Market Trends
14.5.4.2 Market Forecast
15 SWOT Analysis
15.1 Overview
15.2 Strengths
15.3 Weaknesses
15.4 Opportunities
15.5 Threats
16 Value Chain Analysis
16.1 Exploratory Stage
16.2 Preclinical and Clinical Development
16.3 Regulatory Approval
16.4 Manufacturing
16.5 Marketing and Distribution
17 Porters Five Forces Analysis
17.1 Overview
17.2 Bargaining Power of Buyers
17.3 Bargaining Power of Suppliers
17.4 Degree of Competition
17.5 Threat of New Entrants
17.6 Threat of Substitutes
18 Price Analysis
19 Major Drivers and Challenges
20 Competitive Landscape
20.1 Market Structure
20.2 Key Players
20.3 Profiles of Key Players
20.3.1 Abbott Laboratories
20.3.1.1 Company Overview
20.3.1.2 Product Portfolio
20.3.1.3 Financials
20.3.1.4 SWOT Analysis
20.3.2 Astellas Pharma Inc.
20.3.2.1 Company Overview
20.3.2.2 Product Portfolio
20.3.2.3 Financials
20.3.2.4 SWOT Analysis
20.3.3 AstraZeneca Plc
20.3.3.1 Company Overview
20.3.3.2 Product Portfolio
20.3.3.3 Financials
20.3.3.4 SWOT Analysis
20.3.4 Bharat Biotech International
20.3.4.1 Company Overview
20.3.4.2 Product Portfolio
20.3.5 Bavarian Nordic A/S
20.3.5.1 Company Overview
20.3.5.2 Product Portfolio
20.3.5.3 Financials
20.3.6 CSL Limited
20.3.6.1 Company Overview
20.3.6.2 Product Portfolio
20.3.6.3 Financials
20.3.6.4 SWOT Analysis
20.3.7 Daiichi Sankyo Company Limited
20.3.7.1 Company Overview
20.3.7.2 Product Portfolio
20.3.8 Emergent BioSolutions Inc.
20.3.8.1 Company Overview
20.3.8.2 Product Portfolio
20.3.8.3 Financials
20.3.8.4 SWOT Analysis
20.3.9 GlaxoSmithKline Plc
20.3.9.1 Company Overview
20.3.9.2 Product Portfolio
20.3.9.3 Financials
20.3.9.4 SWOT Analysis
20.3.10 Inovio Pharmaceuticals Inc.
20.3.10.1 Company Overview
20.3.10.2 Product Portfolio
20.3.10.3 Financials
20.3.10.4 SWOT Analysis
20.3.11 Johnson & Johnson
20.3.11.1 Company Overview
20.3.11.2 Product Portfolio
20.3.11.3 Financials
20.3.11.4 SWOT Analysis
20.3.12 Merck & Co. Inc.
20.3.12.1 Company Overview
20.3.12.2 Product Portfolio
20.3.12.3 Financials
20.3.12.4 SWOT Analysis
20.3.13 Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
20.3.13.1 Company Overview
20.3.13.2 Product Portfolio
20.3.13.3 Financials
20.3.13.4 SWOT Analysis
20.3.14 Novavax Inc.
20.3.14.1 Company Overview
20.3.14.2 Product Portfolio
20.3.14.3 Financials
20.3.14.4 SWOT Analysis
20.3.15 Panacea Biotec Ltd.
20.3.15.1 Company Overview
20.3.15.2 Product Portfolio
20.3.16 Pfizer Inc.
20.3.16.1 Company Overview
20.3.16.2 Product Portfolio
20.3.16.3 Financials
20.3.16.4 SWOT Analysis
20.3.17 Sanofi Pasteur SA (Sanofi SA)
20.3.17.1 Company Overview
20.3.17.2 Product Portfolio
20.3.17.3 Financials
20.3.17.4 SWOT Analysis
20.3.18 Serum Institute of India Pvt. Ltd.
20.3.18.1 Company Overview
20.3.18.2 Product Portfolio
20.3.19 Takeda Pharmaceutical Company Limited
20.3.19.1 Company Overview
20.3.19.2 Product Portfolio
20.3.19.3 Financials
20.3.19.4 SWOT Analysis